title: Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.
abstract: Preliminary reports suggested that hepatitis C virus (HCV) infection has a more aggressive course following living donor liver transplantation (LDLT) compared to cadaveric liver transplantation (CLT). The aim of this prospective study was to establish if HCV disease recurrence differs between LDLT and CLT. A cohort of 116 consecutive HCV-infected patients undergoing 117 LTs in a single center from March 2000 to August 2003 were followed-up, including systematic liver biopsies. Severe recurrence (SR) was defined as biopsy-proven cirrhosis and/or the occurrence of clinical decompensation. After a median follow-up of 22 months (2.6-44 months), 26 (22%) patients developed SR (decompensation in 12), involving 17 (18%) of 95 patients undergoing CLT and 9 (41%) of 22 undergoing LDLT. The 2-year probability of presenting SR was significantly higher in LDLT compared to CLT (45% vs. 22%, P = .019). By univariate analysis LDLT (P = .019) and an ALT higher than 80 IU/L 3 months after LT (P = .022) were predictors of SR. In 93 patients from whom a liver biopsy was available 3 months after LT, a lobular necroinflammatory score >1 (P < .01), LDLT (P < .01), and biliary complications (P = .046) were associated with SR. However, the only variables independently associated with SR were LDLT (odds ratio [OR], = 2.8; 95% CI,1.19-6.6; P = .024) and a lobular necroinflammatory score > 1 (OR, 3.1; 95% CI, 1.2-8; P = .013). In conclusion, HCV recurrence is more severe in LDLT compared to CLT. Although our results were based on a single-center experience, they should be considered in the decision-making process of transplant programs, since severe HCV recurrence may ultimately compromise graft and patient survival.
authors.affiliation: Liver Unit, Hospital Clinic, Institut de Malalties Digestives, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Garcia-Retortillo
authors.forename: Xavier
authors.initials: X
authors.lastname: Forns
authors.forename: Josep M
authors.initials: JM
authors.lastname: Llovet
authors.forename: Miquel
authors.initials: M
authors.lastname: Navasa
authors.forename: Anna
authors.initials: A
authors.lastname: Feliu
authors.forename: Anna
authors.initials: A
authors.lastname: Massaguer
authors.forename: Miquel
authors.initials: M
authors.lastname: Bruguera
authors.forename: Josep
authors.initials: J
authors.lastname: Fuster
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Garcia-Valdecasas
authors.forename: Antoni
authors.initials: A
authors.lastname: Rimola
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D015994:Incidence; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D018937:Hepatitis C Antibodies